

PIAS4 Antibody (N-term) Blocking peptide
Synthetic peptide
Catalog # BP14013a

Specification

PIAS4 Antibody (N-term) Blocking peptide - Product Information

Primary Accession [Q8N2W9](#)

PIAS4 Antibody (N-term) Blocking peptide - Additional Information

Gene ID 51588

Other Names

E3 SUMO-protein ligase PIAS4, 632-, PIASy, Protein inhibitor of activated STAT protein 4, Protein inhibitor of activated STAT protein gamma, PIAS-gamma, PIAS4, PIASG

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP14013a was selected from the N-term region of PIAS4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

PIAS4 Antibody (N-term) Blocking peptide - Protein Information

Name PIAS4 {ECO:0000303|PubMed:32832608, ECO:0000312|HGNC:HGNC:17002}

Function

Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor (PubMed:12511558, PubMed:12631292, PubMed:12727872, PubMed:15831457, PubMed:15976810, PubMed:22508508, PubMed:32832608). Mediates sumoylation of CEBPA, PARK7, HERC2, MYB, TCF4 and RNF168 (PubMed:12511558, PubMed:12631292, PubMed:>12727872, PubMed:>15831457, PubMed:>15976810, PubMed:>22508508). Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53/TP53 pathway, the Wnt pathway and the steroid hormone signaling pathway (PubMed:>11388671). Involved in gene silencing (PubMed:>11248056). In Wnt signaling, represses LEF1 and enhances TCF4 transcriptional activities through promoting their sumoylations (PubMed:>12727872, PubMed:>15831457). Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation (PubMed:>21965678). Binds to AT-rich DNA sequences, known as matrix or scaffold attachment regions (MARs/SARs) (By similarity). Catalyzes conjugation of SUMO2 to KAT5 in response to DNA damage, facilitating repair of DNA double-strand breaks (DSBs) via homologous recombination (HR) (PubMed:>32832608). Mediates sumoylation of PARP1 in response to PARP1 trapping to chromatin (PubMed:>35013556).

Cellular Location

Nucleus, PML body Note=Colocalizes with SUMO1 and TCF7L2/TCF4 and LEF1 in a subset of PML (promyelocytic leukemia) nuclear bodies.

Tissue Location

Highly expressed in testis and, at lower levels, in spleen, prostate, ovary, colon and peripheral blood leukocytes

PIAS4 Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

PIAS4 Antibody (N-term) Blocking peptide - Images

PIAS4 Antibody (N-term) Blocking peptide - Background

PIAS4 functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway, the Wnt pathway and the steroid hormone signaling pathway. Involved in gene silencing. Promotes PARK7 sumoylation. In Wnt signaling, represses LEF1 and enhances TCF4 transcriptional activities through promoting their sumoylations.

PIAS4 Antibody (N-term) Blocking peptide - References

Kang, X., et al. Oncogene 29(41):5568-5578(2010)Liu, Y., et al. J. Invest. Dermatol. 130(5):1384-1390(2010)Zhang, C., et al. Cell. Immunol. 263(2):235-240(2010)Wang, J., et al. J. Biol. Chem. 283(34):23235-23243(2008)Imoto, S., et al. Biochem. Biophys. Res. Commun. 370(2):359-365(2008)